Prime Genomics is an innovative, early-stage company specializing in genomics and molecular diagnostics, focusing on developing breakthrough approaches for cancer screening. The company operates in the biotechnology sector, targeting healthcare providers, research institutions, and clinical laboratories. Prime Genomics employs advanced genomics techniques to create noninvasive cancer detection methods, aiming to revolutionize early cancer diagnosis and improve patient outcomes. The business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary screening technologies. Revenue is generated through partnerships, licensing agreements, and sales of diagnostic tests.

Keywords: genomics, molecular diagnostics, cancer screening, noninvasive detection, biotechnology, healthcare, clinical trials, early diagnosis, RNA assays, patient outcomes.